The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

goserelin     N-[1-[[1-[[1-[[1-[[1-[[1-[[1- [2...

Synonyms: Goserelina, Gosereline, Goserelinum, Decapeptide I, HSDB 7606, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of goserelin


Psychiatry related information on goserelin


High impact information on goserelin


Chemical compound and disease context of goserelin


Biological context of goserelin

  • RESULTS: After 2 years of treatment, there was a significant loss of bone mineral density (mean change, -5%; P <.001) in the women receiving goserelin alone [20].
  • In radioligand binding assays using GnRHa goserelin, no pituitary-like, high-affinity GnRH binding sites could be found in either EC cell lines or tissues [21].
  • The antiproliferative action of the two LHRH agonists was shown to be dose dependent, with IC50 values of 0.82 and 1.79 nM for Z and B, respectively [18].
  • However, goserelin may be a useful treatment for women approaching menopause, in whom uterine leiomyomata shrink naturally as endogenous estrogen levels decline [7].
  • Zoladex-flutamide treatment required 3 weeks to suppress the completion of spermatogenesis; only a small degree of suppression was observed with Zoladex alone [22].

Anatomical context of goserelin

  • The combination of Zoladex treatment with procarbazine was successful in preserving testicular function in the piebald variegated rats as virtually all the functional and morphological parameters of both the seminiferous tubule and the Leydig cell were not significantly different from those of vehicle-treated rats [23].
  • As adjuvant therapy for women undergoing assisted reproduction procedures, goserelin is associated with reduced cycle cancellation rates and with an increase in the rate of oocyte retrieval [7].
  • Stimulation of cholesterol side-chain cleavage by a luteinizing-hormone-releasing hormone (luliberin) agonist (ICI 118630) in rat Leydig cells [24].
  • Treatment of the animals with AGT or goserelin did not cause a significant effect on the development of either putative preneoplastic acinar lesions in rat pancreas or early ductular lesions in hamster pancreas [25].
  • In women with dysfunctional uterine bleeding, treatment with depot goserelin before surgery facilitates resection and ablative procedures by suppressing endometrial growth and thinning the endometrial mucosa [7].

Associations of goserelin with other chemical compounds


Gene context of goserelin

  • Hypogonadal (hpg) mutant mice, with a congenital deficiency of hypothalamic gonadotrophin-releasing hormone (GnRH), and testicular feminized (tfm) mice, which lack a functional androgen receptor, were used to study the effects of the potent GnRH agonist 'Zoladex' (ICI 118630; D-Ser (Bu(t))6, Azgly10-GnRH) on pituitary and gonadal function [30].
  • METHODS: hTERT immunostaining was performed on the cancerous pretreatment biopsy tissue of 30 men who consecutively underwent CAA with bicalutamide and goserelin acetate for 30 days prior to undergoing radical prostatectomy, and on their tumor tissue from radical prostatectomy [31].
  • Other promising chemopreventive agents currently under investigation include cyclo-oxygenase 2 (COX-2) inhibitors, fenretinide, aromatase inhibitors, and goserelin [32].
  • CONCLUSION: Our data suggest that MRP1 expression plays an important role in the clinical resistance to adjuvant CMF chemotherapy but does not seem to affect response to adjuvant endocrine treatment with tamoxifen plus goserelin [33].
  • RESULTS: DU-145 cells, overexpressing wild-type EGFR, formed tumors in athymic mice that were inhibitable by goserelin acetate (Zoladex) [27].

Analytical, diagnostic and therapeutic context of goserelin


  1. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. Bolla, M., Gonzalez, D., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., Collette, L., Pierart, M. N. Engl. J. Med. (1997) [Pubmed]
  2. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D. N. Engl. J. Med. (1999) [Pubmed]
  3. Goserelin therapy before surgery for uterine fibroids. Lumsden, M.A., West, C.P., Baird, D.T. Lancet (1987) [Pubmed]
  4. Pituitary apoplexy after goserelin. Ando, S., Hoshino, T., Mihara, S. Lancet (1995) [Pubmed]
  5. Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. Saphner, T., Troxel, A.B., Tormey, D.C., Neuberg, D., Robert, N.J., Pandya, K.J., Edmonson, J.H., Rosenbluth, R.J., Abeloff, M.D. J. Clin. Oncol. (1993) [Pubmed]
  6. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. Nystedt, M., Berglund, G., Bolund, C., Fornander, T., Rutqvist, L.E. J. Clin. Oncol. (2003) [Pubmed]
  7. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry, C.M., Brogden, R.N. Drugs (1996) [Pubmed]
  8. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Mansel, R.E., Goyal, A., Preece, P., Leinster, S., Maddox, P.R., Gateley, C., Kubista, E., von Fournier, D. Am. J. Obstet. Gynecol. (2004) [Pubmed]
  9. Goserelin-induced new-onset depressive disorder. Kohen, I., Koppel, J. Psychosomatics. (2006) [Pubmed]
  10. Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. Rosin, R.A., Raskind, M.A. International psychogeriatrics / IPA. (2005) [Pubmed]
  11. Treatment of prostate cancer with goserelin and radiotherapy. Schoen, S.S. N. Engl. J. Med. (1997) [Pubmed]
  12. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. Grignon, D.J., Caplan, R., Sarkar, F.H., Lawton, C.A., Hammond, E.H., Pilepich, M.V., Forman, J.D., Mesic, J., Fu, K.K., Abrams, R.A., Pajak, T.F., Shipley, W.U., Cox, J.D. J. Natl. Cancer Inst. (1997) [Pubmed]
  13. Partial remission of parotid gland carcinoma after goserelin. van der Hulst, R.W., van Krieken, J.H., van der Kwast, T.H., Gerritsen, J.J., Baatenburg de Jong, R.J., Lycklama à Nijeholt, A.A., Meinders, A.E. Lancet (1994) [Pubmed]
  14. Catamenial epilepsy and goserelin. Reid, B.A., Gangar, K.F. Lancet (1992) [Pubmed]
  15. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Walker, K.J., Nicholson, R.I., Turkes, A.O., Turkes, A., Griffiths, K., Robinson, M., Crispin, Z., Dris, S. Lancet (1983) [Pubmed]
  16. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. Pohl, G., Rudas, M., Dietze, O., Lax, S., Markis, E., Pirker, R., Zielinski, C.C., Hausmaninger, H., Kubista, E., Samonigg, H., Jakesz, R., Filipits, M. J. Clin. Oncol. (2003) [Pubmed]
  17. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. de Haes, H., Olschewski, M., Kaufmann, M., Schumacher, M., Jonat, W., Sauerbrei, W. J. Clin. Oncol. (2003) [Pubmed]
  18. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Limonta, P., Dondi, D., Moretti, R.M., Maggi, R., Motta, M. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  19. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Rosenthal, S.A., Linstadt, D.E., Leibenhaut, M.H., Andras, E.J., Brooks, C.P., Stickney, D.R., Chang, G.C., Wolkov, H.B., Gilbert, R.M. Radiology. (1996) [Pubmed]
  20. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. Sverrisdóttir, A., Fornander, T., Jacobsson, H., von Schoultz, E., Rutqvist, L.E. J. Clin. Oncol. (2004) [Pubmed]
  21. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Chatzaki, E., Bax, C.M., Eidne, K.A., Anderson, L., Grudzinskas, J.G., Gallagher, C.J. Cancer Res. (1996) [Pubmed]
  22. Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat. Kangasniemi, M., Wilson, G., Huhtaniemi, I., Meistrich, M.L. Endocrinology (1995) [Pubmed]
  23. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Ward, J.A., Robinson, J., Furr, B.J., Shalet, S.M., Morris, I.D. Cancer Res. (1990) [Pubmed]
  24. Stimulation of cholesterol side-chain cleavage by a luteinizing-hormone-releasing hormone (luliberin) agonist (ICI 118630) in rat Leydig cells. Sullivan, M.H., Cooke, B.A. Biochem. J. (1983) [Pubmed]
  25. Effects of castration, alone and in combination with aminoglutethimide, on growth of (pre)neoplastic lesions in exocrine pancreas of rats and hamsters. Meijers, M., Woutersen, R.A., van Garderen-Hoetmer, A., Bakker, G.H., de Jong, F.H., Foekens, J.A., Klijn, J.G. Carcinogenesis (1991) [Pubmed]
  26. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Romeo, D., Sismondi, P., Giai, M., Genta, F., Pacini, P., Distante, V., Bolognesi, A., Aldrighetti, D., Farris, A. J. Clin. Oncol. (2000) [Pubmed]
  27. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Wells, A., Souto, J.C., Solava, J., Kassis, J., Bailey, K.J., Turner, T. Clin. Cancer Res. (2002) [Pubmed]
  28. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H). Geldof, A.A., de Voogt, H.J., Rao, B.R. Prostate (1987) [Pubmed]
  29. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. Peternac, D., Klima, I., Cecchini, M.G., Studer, U.E., Thalmann, G.N. J. Urol. (2006) [Pubmed]
  30. Effects of the gonadotrophin-releasing hormone agonist 'Zoladex' upon pituitary and gonadal function in hypogonadal (hpg) male mice: a comparison with normal male and testicular feminized (tfm) mice. Scott, I.S., Bennett, M.K., Porter-Goff, A.E., Harrison, C.J., Cox, B.S., Grocock, C.A., O'Shaughnessy, P.J., Clayton, R.N., Craven, R., Furr, B.J. J. Mol. Endocrinol. (1992) [Pubmed]
  31. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. Iczkowski, K.A., Huang, W., Mazzucchelli, R., Pantazis, C.G., Stevens, G.R., Montironi, R. Cancer (2004) [Pubmed]
  32. Risk-reducing strategies for breast cancer--a review of recent literature. Mokbel, K. International journal of fertility and women's medicine. (2003) [Pubmed]
  33. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C.C., Hausmaninger, H., Kubista, E., Samonigg, H., Jakesz, R. J. Clin. Oncol. (2005) [Pubmed]
  34. Treatment of breast cancer with gonadotropin-releasing hormone. Manni, A., Santen, R., Harvey, H., Lipton, A., Max, D. Endocr. Rev. (1986) [Pubmed]
  35. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. Chodak, G.W., Vogelzang, N.J., Caplan, R.J., Soloway, M., Smith, J.A. JAMA (1991) [Pubmed]
  36. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Ahmed, S.R., Brooman, P.J., Shalet, S.M., Howell, A., Blacklock, N.J., Rickards, D. Lancet (1983) [Pubmed]
  37. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. Berglund, G., Nystedt, M., Bolund, C., Sjödén, P.O., Rutquist, L.E. J. Clin. Oncol. (2001) [Pubmed]
WikiGenes - Universities